Insider · CIK 0001569248
Kristina Burow
directorowner
Files at SRRK (Scholar Rock Holding Corp), BOLD (Boundless Bio, Inc.), NMRA (Neumora Therapeutics, Inc.), PRME (Prime Medicine, Inc.), MTSR (Metsera, Inc.). First filing Feb 3, 2025, latest May 30, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 1
$40M bought, $161k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SRRK: Scholar Rock Holding Corp
SRRKOct 9, 2026 · close 42.19
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 26Weak | Scholar Rock Holding Corp | $161k 5,400 shares | -20% | +322% from low-36% from high | |
| 58Moderate | Metsera, Inc. | $40M 2,222,222 shares | +13% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 23, 2025 | BOLD Boundless Bio, Inc. | AGrant or award Stock Option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 23, 2025 |
| May 29, 2025 | SRRK Scholar Rock Holding Corp | SOpen-market sale Common Stock10b5-1 | -1,000 | $29.24 | $29k | 25,471 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -46,455 | - | - | 0 | May 30, 2025 |
| May 29, 2025 | SRRK Scholar Rock Holding Corp | SOpen-market sale Common Stock10b5-1 | -4,400 | $29.83 | $131k | 21,071 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,571 | - | - | 0 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +46,455 | - | - | 46,455 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +28,571 | - | - | 28,571 | May 30, 2025 |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | May 30, 2025 |
| May 22, 2025 | SRRK Scholar Rock Holding Corp | AGrant or award Common Stock | +7,632 | $0.00 | $0 | 26,471 | May 23, 2025 |
| May 22, 2025 | SRRK Scholar Rock Holding Corp | AGrant or award Stock Option (Right to Buy)derivative | +9,206 | $0.00 | $0 | 9,206 | May 23, 2025 |
| May 20, 2025 | MTSR Metsera, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +16,125 | $0.00 | $0 | 16,125 | May 22, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -46,455 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,571 | - | - | 0 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +46,455 | - | - | 46,455 | Feb 18, 2025 |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +28,571 | - | - | 28,571 | Feb 18, 2025 |
| Feb 3, 2025 | MTSR Metsera, Inc. | CConversion Common Stockindirect: See footnote | +16,006,949 | - | - | 17,070,904 | Feb 3, 2025 |
| Feb 3, 2025 | MTSR Metsera, Inc. | POpen-market purchase Common Stockindirect: See footnote | +1,432,224 | $18.00 | $26M | 18,503,128 | Feb 3, 2025 |
| Feb 3, 2025 | MTSR Metsera, Inc. | CConversion Common Stockindirect: See footnote | +7,523,682 | - | - | 7,523,682 | Feb 3, 2025 |
| Feb 3, 2025 | MTSR Metsera, Inc. | POpen-market purchase Common Stockindirect: See footnote | +789,998 | $18.00 | $14M | 8,313,680 | Feb 3, 2025 |
| Feb 3, 2025 | MTSR Metsera, Inc. | CConversion Series Seed Preferred Stockderivativeindirect: See footnote | -19,933,333 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | MTSR Metsera, Inc. | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnote | -15,000,000 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | MTSR Metsera, Inc. | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -2,678,571 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | MTSR Metsera, Inc. | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnote | -15,000,000 | - | - | 0 | Feb 3, 2025 |
| Feb 3, 2025 | MTSR Metsera, Inc. | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -2,678,571 | - | - | 0 | Feb 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.